News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Study Confirms Skinvisible, Inc.'s Patent-Pending Chlorhexidine Hand Sanitizer Kills The Avian 'Bird Flu' Virus H5N1 On Contact For Up To Four Hours


6/5/2006 12:26:28 PM

LAS VEGAS, June 5 /PRNewswire-FirstCall/ -- A new hand sanitizer could offer greater protection against the spread of the 'bird flu' virus H5N1 through personal contact with carriers of the virus, according to study results released today by Skinvisible Pharmaceuticals, Inc. . The Las Vegas-based research and development company for topical skin applications announced that its patent-pending Chlorhexidine Antimicrobial Hand Sanitizer had a greater than 98 percent inactivation/kill on the "bird flu" virus H5N1 for up to four hours on skin.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO )

The new study, conducted by Retroscreen Virology, a subsidiary of University of London's Queen Mary School of Medicine, differentiates the Chlorhexidine Antimicrobial Hand Sanitizer from other medicinal scrubs or alcohol-based sanitizers and treatments on the market, which only offer protection upon immediate application to the skin. According to Retroscreen, "antiviral hand care products that are shown to inactivate H5N1 will be an important weapon in stopping the spread of this virus. The longer the duration the active stays on the skin to kill the virus the better."

As major international organizations such as the World Health Organization and the Center for Disease Control warn that the H5N1 virus may prove to be the source of the next human catastrophe, Skinvisible is looking to establish its Chlorhexidine Antimicrobial Hand Sanitizer as an essential product for the healthcare industry to inactivate/kill this virus if it should become resident on the hands. This could stop person to person cross contamination.

"We are pleased with these latest studies and are hopeful that by June 30 we will have completed all studies currently underway with success so we can approach the necessary health authorities worldwide for the appropriate approval process to make this product available to all consumers." says Terry Howlett, President and CEO of Skinvisible.

Skinvisible Pharmaceuticals developed this antimicrobial hand sanitizer formula, primarily for the healthcare industry, using 2.25 percent Chlorhexidine as the active ingredient. Chlorhexidine is a non-toxic antiseptic that kills or inhibits the growth of disease-causing bacteria, viruses and other microorganisms, and is used for surgical scrub, skin wounds, germicidal hand rinse, and antibacterial dental rinse. Skinvisible's proprietary Invisicare(R) family of polymer delivery vehicles allow the formulations to stay on the skin for extended periods of time, as shown in this latest study.

According to the Center for Disease Control, the common seasonal influenza flu virus kills nearly one million people globally every year, and Skinvisible believes its Chlorhexidine Hand Sanitizer may offer an alternative to the alcohol-based hand sanitizers now used worldwide in the healthcare industry. Skinvisible's product also has been tested against a variety of bacteria of concern to the healthcare industry, including the Super Bugs, VRE and MRSA. The product will be undergoing further tests soon against other viruses, including Norovirus (Norwalk), Rhinovirus, Influenza A (H1 and H3), H2 and Influenza B.

About Retroscreen Virology Ltd.

London-based Retroscreen Virology is Europe's leading contract virology research company, created in 1989 from St. Bartholomew's Hospital and the Royal London Hospital by Professor John Oxford, a world-renowned influenza virologist. Retroscreen Virology, which specializes in laboratory and clinic- based respiratory virology research, is the only company in the UK that is able to conduct human influenza challenge studies in a specialized quarantine unit with A/Panama/2007/99 and A/New Caledonia/20/99 viruses, and has characterized influenza A (H1N1 and H3N2) and B viruses. Contact: Dr. Rob Lambkin Managing Director. Tel: 001-44-20-7882-7966.

About Invisicare(R)

At the heart of Skinvisible's patented technology and trademarked Invisicare(R) family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. This allows formulated products using Invisicare(R) as their platform to remain on the skin for extended periods of time, thereby affording active agents a prolonged timeframe to perform their intended functions. Products utilizing Invisicare(R) have the proven ability to bond active ingredients to the skin for up to four or more hours. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, these formulated products adhere to the skin's outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. They allow enhanced delivery performance for a variety of skincare agents resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The "invisible" polymer compositions wear off as part of the natural exfoliation process of the skin's outer layer cells.

About Skinvisible Pharmaceuticals, Inc.

Headquartered in Las Vegas, Nevada, Skinvisible Pharmaceuticals is a research-and-development company that has formulated and patented innovative polymer delivery system technology and compositions for topical skin applications. Skinvisible's primary marketing and sales objective is to license its technology and sell its trademarked polymer delivery vehicle Invisicare(R) to established dermatological, cosmetic, skincare and pharmaceutical manufacturers. For more information, visit: www.skinvisible.com.

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10QSB for the quarter ending March 31, 2006.

Media Contact: Corporate Contact: Kelly Krueger Terry Howlett, President/CEO Weber Shandwick for Skinvisible Skinvisible Pharmaceuticals, Inc. 415.248.3415 702-433-7154 kkrueger@webershandwick.comterry@skinvisible.com

Photo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSkinvisible Pharmaceuticals, Inc.

CONTACT: Media, Kelly Krueger of Weber Shandwick, +1-415-248-3415,kkrueger@webershandwick.com, for Skinvisible Pharmaceuticals, Inc.; orTerry Howlett, President/CEO of Skinvisible Pharmaceuticals, Inc.,+1-702-433-7154, terry@skinvisible.com


Read at BioSpace.com

comments powered by Disqus
   
Bird Flu

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES